Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...
Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse events Breadth of responses observed across tumor ...
Over 1.2 million people in the US are living with melanoma, according to the National Cancer Institute‘s 2015 estimates, with the number of new cases steadily increasing. NCI estimates that 91,270 ...
BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...
Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care. Neoadjuvant (primary ...
“Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression” “Inhibitors ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
The selective BRAF inhibitors vemurafenib (Zelboraf, Roche/Plexxikon) and dabrafenib (Tafinlar, GlaxoSmithKline) have significantly improved survival in patients with BRAF V600–mutant metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results